

DAVID JOEL WITT, M.D., FIDSA, CIC  
Citizenship: US, German

EDUCATION

1984-86 Boston City Hospital, Boston, MA, Clinical Fellow in Infectious Diseases  
1980-82 Boston City Hospital, Boston, MA, Junior and Senior Assistant Resident  
1979-80 Boston Univ. Affiliated Hospitals Program, Malden, MA Intern  
1975-79 University of Michigan Medical School, Ann Arbor, MI, Degree: MD  
1970-74 University of Pittsburgh, Pittsburgh, PA, Degree: B.S. Chemistry

BOARD CERTIFICATION

Board Certified:

Certification in Infection Control, 2016  
Certification in Tropical Medicine and Traveler's Health, 2008  
Sub-specialty Certification, Infectious Diseases, 1992, 2001, 2012  
American Board of Emergency Medicine, 1999, #11871  
American Board of Internal Medicine, 1983, #085434  
National Board of Medical Examiners, 1980, #212686

CLINICAL APPOINTMENTS

1992-2017 University of California at San Francisco, Associate Clinical Professor,  
School of Nursing  
2000-2018 University of California at San Francisco, Assistant Clinical Professor,  
School of Medicine  
1984-1987 Boston University School of Medicine, Instructor in Medicine

CURRENT LICENSURE

California G046814 Exp: 10/31/23  
DEA AW1871347 Exp: 05/31/25  
Massachusetts 47839 Exp: Inactive

PROFESSIONAL POSITIONS

2020- Present National Biodefense Science Board member.  
Office of the Assistant Secretary for Preparedness and Response (ASPR)  
2020- Present Subject Matter Expert, Marin County COVID Vaccination Task Force  
2019- Present Trustee, Marin/Sonoma Vector Control District  
2020- 2021 Chief Medical Officer, National Kaiser Permanente COVID Response  
2017- 2021 Regional Healthcare Epidemiologist, Kaiser Permanente Northern  
California Region. Oversight and support for all infection control issues and  
consultative support for outbreak investigation.  
2004-2017 Chief, Infectious Diseases, Kaiser Permanente Med. Cent., San Rafael  
2013 Independent Program Reviewer for two projects. Comic Relief, donor:  
Improving Malaria Treatment through use of the Private Sector; and, A  
novel Pesticide-impregnated durable lining for houses. Monrovia, Liberia

PROFESSIONAL POSITIONS, continued

- 2010 Clinical Coordinator, MENTOR Initiative Emergency Team,  
Developed and implemented Dengue and malaria prevention and  
treatment programs in Haiti after the Haitian earthquake
- 2008 Clinical Director, MENTOR Initiative Emergency Team,  
Developed and implemented Dengue and malaria prevention and  
treatment programs in Myanmar for Cyclone Nargis
- 2007 Clinical Director, MENTOR Initiative Emergency Team,  
Developed and implemented a malaria prevention and treatment program  
in Garissa District, Somali Border area, Kenya
- 2006-2010 Technical Auditor, US Department of State, International Science and  
Technology Center, Russian Federation, Kyrgyzstan and Tatarstan.  
Audited non-proliferation effort which funds non-weapons activities for  
former biologic weapon scientists and laboratories in the former Soviet Union.  
Audit was for integrity of the funding, the scientific validity of the project,  
verification that weapons work was not being performed and that former  
weapons scientists were performing the activities.
- 2005 Clinical Lead, Hurricane Katrina and Rita Relief Team, Houston, Texas
- 2005 Clinical Director, MENTOR Initiative Emergency Team, (Developed and  
implemented a malaria prevention and treatment program, Aceh province,  
Indonesia)
- 1997-98 Asst. Chief, Dept. of Medicine, Kaiser Permanente Med. Cent., SSF, CA
- 2000-4 Chair, Infectious Disease Chiefs, Northern California Permanent  
1989-94 Medical Group
- 1987- 2004 Chief, Infectious Diseases, Kaiser Permanente Med. Cent., SSF, CA
- 1998- 2010 Medical Director, South San Francisco Fire Department
- 1987-95 Chief, Emergency Department, Kaiser Permanente Med. Cent., SSF, CA
- 1987-95 Medical Director, Sub-Regional After-Hours Advice Center
- 1986-87 Emergency Department Director, Woodland Memorial Hospital, Woodland, CA
- 1986-87 Regional Director, Valley Emergency Physicians Medical Group, Oakland, CA
- 1986-87 Medical Director, Yolo Ambulance Services, Yolo County, CA
- 1986 Locum Tenens, Infectious Disease, Carney Hospital, Boston, MA

PROFESSIONAL POSITIONS, continued

- 1985-86      Attending Physician, Emergency Dept., Boston City Hospital, Boston, MA
- 1983-84      Emergency Department Director, Oak Valley District Hospital, Oakdale, CA
- 1983-84      Preceptor, Medical Clinic, St. Mary's Hospital, San Francisco, CA
- 1982-84      Emergency Physician, Valley Emergency Physicians Medical Group, Berkeley, CA
- 1981-82      Emergency Physician, Carney Hospital, Boston, MA
- 1974-75      Research Assistant, Dept. of Toxicology, Univ. of Pittsburgh, School of Public Health, Pittsburgh, PA

CONSULTANT

- 2020-present      Golden Spear. Artificial intelligence development for disease detection and control
- 1994-98      Oceania Corporation, Palo Alto, CA  
Clinical Users Group for development of a clinical information system
- 1985-6      State of Massachusetts, Department of Public Health, Department of Drug Rehabilitation; Policy Development and Staff Training for AIDS and Other Infectious Diseases

TEACHING AND PROFESSIONAL ACTIVITIES

Scientific Reviewer:

Vaccine  
Clinical Infectious Diseases  
Annals of Emergency Medicine  
Pediatrics  
Journal of Infection  
Transplant Infectious Diseases  
Preventative Medicine Reports  
American Journal of Managed Care  
Open Forum Infectious Diseases (OFID)  
The Permanente Journal

- 2000-2018      Attending Physician, Ft. Miley Veterans Hospital, San Francisco, CA
- 1988-2018      Nurse Practitioner Preceptor, Univ. of California at San Francisco, School of Nursing
- 1988-2009      ACLS Course Medical Director, Kaiser Permanente Med. SSF, CA
- 1987-93      Examiner and Reviewer, Board of Medical Quality Assurance, State of California

TEACHING AND PROFESSIONAL ACTIVITIES, continued

- 1986 Member, Massachusetts Department of Public Health, Task Force on AIDS and the Needle Drug Abuser
- 1985 Testimony, House Officers Assn, Massachusetts Legislative Subcommittee On Health Affairs

CERTIFICATION

- 2010 Patient Safety Executive, Institute for Healthcare Improvement
- 2008 Tropical Medicine and Traveler's Health
- 1990 Hospital Epidemiology Training Course, Centers for Disease Control,
- 1989 Physicians' Management Course, Permanente Medical Group

HONORS

- 2021 Barry Farr award, SHEA. Best international paper. (Senior author)
- 2016 Outstanding Contribution to Community Health Marin Medical Society
- 2007 Corporate Partner Award, California Medical Association Foundation, Anaheim, CA
- 2005 Marin County Community Heroes Recognition, American Red Cross
- 1995 Commendation, South San Francisco Fire Dept., for paramedic support and training
- 1974 Dean's Undergraduate Teaching Fellowship, University of Pittsburgh, Pittsburgh, PA

MEMBERSHIPS

- 2014 European Association for the Study of Liver Disease
- 2013 American Association for the Study of Liver Disease
- 2007 American Society for Tropical Medicine and Hygiene
- 1993 Society for Hospital Epidemiology of America
- 1992 Infectious Diseases Society of America
- 1991-95 American College of Emergency Physicians
- 1991 Bay Area Infectious Disease Society
- 1988 California Medical Association
- 1985 American Society of Microbiology
- 1980 American College of Physicians

## INVESTIGATIONAL STUDIES

### Principal Investigator:

TKM-100802, interfering small RNA. Expanded Access Protocol for Use of TKM-100802 in Patients with Confirmed or Suspected Ebola Virus Infection

### INVESTIGATIONAL STUDIES, continued

P05063 Long –Term Follow-Up of Subjects in a Phase 1,2 or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C

P05126 A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1

MK 003-02 A Dose-Ranging Study to Test the Safety, Tolerability, and Effectiveness of Different Doses of MK-5172 when Given with Peginterferon alpha-2B and Ribavirin in Patients with Hepatitis C Virus Infection

Observational Study of Hepatitis C Treatment with Direct Acting Antivirals in an Integrated Healthcare System in a Community Setting.

IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir in Hepatitis C

### Sub-investigator:

A Retrospective Review of the Relationship Between Statin Treatment, Cholesterol Levels and Bacteremia Outcomes

A phase III, randomized, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection

California Encephalitis Project

### Expanded access Phase 2b and 3 studies

For HIV: Lamivudine  
Lopinavir/ritonavir  
Enfuvirtide  
Tenofovir

Others: Quinupristin/dalfopristin (vancomycin-resistant enterococci)  
Clofazamine (mycobacterium avium)  
Sodium stibogluconate (Leishmaniasis)

## GRANTS AND PROJECTS

1994-1995 Urgent Emergent Re-engineering, Kaiser Permanente.  
Review and design of systems for providing urgent patient care. Demand Management, Information Technology and other developing strategies and technologies for clinical care were all examined.

GRANTS AND PROJECTS, continued

- 1992 Medical Office Clinical Information Systems (MOCIS0, Kaiser Permanente Consensus development and technical specifications for Emergency Department applications of the "MOCIS" automated record.
- 1992 Medical Office Clinical Information Systems (MOCIS), Kaiser Permanente Directed research.  
Examination of alternative educational methods for training physicians in the use of computers.
- 1990-1991 Medical Office Innovation Grant #302, Kaiser Permanente -  
To quantitatively and qualitatively evaluate the benefits of dictation services in the Emergency Department. \$38,796.00
- 1991 Regional Integrated Laboratory Information System (RILIS), Clinical Users Group, Kaiser Permanente  
Consultative committee to facilitate and direct the introduction of a Region-wide laboratory information system.
- 1991 Gateways Project, Kaiser Permanente, Collaborative committee of architects and clinicians for design of modular departments for new hospital construction.
- 1990 Medical Office Innovation Grant #303, Kaiser Permanente - To develop and evaluate a sub-regional overnight advice center, staffed by RNs. \$61,286.00

COMMITTEES, (Selected)

- 2019 Steering Committee, Course Faculty APIC Applied Learning Conference October 26-27, 2019. St Louis, MO
- 2013-2019 Chair 2015-6, Vice Chair 2014-5, Member, Abstracts Committee, Association for Professionals in Infection Control and Epidemiology
- 2012-2019 Chair 2017-8, Vice Chair 2016-7, Member, Annual Meeting Program Committee, Association for Professionals in Infection Control and Epidemiology
- 2008-2017 Co-Chair, Marin County Immunization Task Force
- 2012-2016 Chair,  
2005-2016 Member, California Department of Public Health, Healthcare Associated Infections Advisory Committee,
- 2007-2008 Member, MRSA Expert Advisory Panel, CMA Foundation
- 2001-2019 Member, National Executive Oversight Committee, Kaiser Permanente (Oversees responses to disasters, terrorism and Healthcare Continuity, Chair, Clinical Workgroup of National Executive Oversight Committee

COMMITTEES (Selected), continued

- 1999-2016 Steering Committee and Founding Member, California Medical Foundation, AWARE (Alliance Working for Antibiotic Resistance Education).  
AWARE promotes appropriate use of antibiotics to prevent antibiotic resistance with its CDC partner and a broad-based coalition of Industry, Professional Societies, Consumers and Pharma.
- 2005 – 2007 Member, Pandemic Influenza Planning Task Force, California Department of Health Services
- 2004 - 2005 Member, California Department of Health Services, Public Health and Emergency Preparedness Planning Committee
- 2005-2015 Chair, Emergency Preparedness and Disaster Committee, Kaiser Foundation Hospital, San Rafael, CA
- 2004-2017 Chair, Infection Control Committee, Member, Pharmacy and Therapeutics Committee. Kaiser Foundation Hospital, San Rafael, CA
- 2004-2010 Member, Joint Advisory Committee, (bioterrorism), Marin County, CA.
- 2001-2004 Member, Terrorism Preparedness Task Force, San Mateo County, CA
- 1987-2004 Chair, Infection Control Committee, Member, Executive Committee, Pharmacy and Therapeutics Committee, Utilization Review Committee; Kaiser Permanente Medical Center, South San Francisco, CA
- 1994-1996 Outcomes Cost Management Committee, California Chapter American College of Emergency Physicians
- 1993-1994 Managed Care Committee, San Mateo Medical Society, San Mateo, CA
- 1990-1992 Medical-Legal Liaison Committee, Emergency and Disaster Committee, San Mateo Medical Society, San Mateo, CA
- 1988-1994 Kaiser Permanente, Regional AIDS Committee
- 1987-1990 Medical Advisory Committee, San Mateo Department of Health Services, San Mateo County, CA
- 1987- 2004 Chair, Infection Control Committee,  
Member, Executive Committee, Pharmacy and Therapeutics Committee,  
Kaiser Permanente Medical Center, South San Francisco, CA
- 1986 Emergency Care Committee, Woodland Memorial Hospital Woodland, CA
- 1981-82, 85 Executive Committee, Bargaining Committee, Boston City Hospital House Officers Association

SYMPOSIA TALKS (Selected).

Witt, D., AIDS: An Overview, American Public Health Nurses Association, Annual Meeting, Cambridge, Massachusetts, September 10, 1985

Witt, D., The Clinical Spectrum of HTLV-III Infection, Symposium on the Biology of HTLV-III Infection and its Consequences, Wood's Hole, Massachusetts, February 1, 1986.

Witt, D., AIDS in Needle Drug Users and Prostitutes, guest lecture, Harvard School of Public Health, May 13, 1986.

Witt, D., AIDS in Parenteral Drug Users, guest lecture, Boston University School of Public Health, June 5, 1986.

Witt, D., AIDS in the Workplace, San Francisco, California, March 10, 1988.

Witt, D., Emergency Department Physician Extenders: Alternate Models, Panel Member, American College of Emergency Physicians Scientific Assembly, San Francisco, California, September 16, 1990.

Witt, D., Host Faculty, Preventing Malpractice in Emergency Medicine, San Francisco, California, February 21-23, 1992.

Witt, D., Tuberculosis in Health Care Workers. Cost-Effective Antibiotics Use, Third National Kaiser Permanente Emergency Medicine Conference, San Francisco, California, August 1, 2, 1993.

Witt, D., Cost-Effective Antibiotic Use, Emergency Medicine Grand Rounds, Stanford University, Stanford, California, February 9, 1994.

Witt, D., Difficult Cases in Infectious Diseases, Cost-Effective Infectious Disease Workups, Fourth National Kaiser Permanente Emergency Medicine Conferences, Vail, Colorado, August 14-17, 1994.

Witt, D., Tuberculosis Infectious Disease Symposium, Continuing Education for Laboratory Personnel, Oakland and Sacramento California, October 19-20, 1994.

Witt, D., Case Discussions, Eleventh Annual Advances In Emergency Medicine, University of California at San Francisco, California, April 6, 1995.

Witt, D., Emerging and Re-emerging Infectious Diseases, Including Biologic Warfare. Northern California Division, American Society for Microbiology, Sacramento, CA, September 19, 1998.

Testimony, Observations on Vaccinia Vaccine Program, Institute of Medicine, May 1, 2003, Washington, DC.

Witt, D., Emerging Infectious Diseases, University of California, Center for Environmental and Environmental Health, Oakland, CA, July 30, 2004.



SYMPOSIA TALKS (Selected), continued

Panel member. National Healthcare Policy Forum. Pandemic Influenza Planning, Washington, DC, November 1, 2004.

Course Director, Emerging Infectious Diseases, What Occupational Safety and Health Professionals Need to Know, University of California, Center for Environmental and Environmental Health, Oakland, CA, July 25-6, 2005.

Course Faculty, Workshop on Malaria Control, The MENTOR Initiative, November 26-27, 2005. Tokyo, Japan.

Presentation, Pandemic Flu, Business Continuity and Crisis Management Council, The Conference Board, June 1-2, 2006, Dallas, Texas

Panel member, Preparing for Pandemic Flu: Collaboration and Tension between Health Care Providers and Public Health Authorities. California Society for Healthcare Attorneys, October 27, 2006, Burlingame, CA

Course Faculty and Sponsor, Five-day intensive training workshop on Malaria in Complex Emergencies, The MENTOR Initiative, Entebbe, Uganda, February 2007, Mill Valley, CA October 2007, Washington, DC. March 2008, Thailand, February 2010, Nairobi, Kenya, November 2011, Dar es Salaam, Tanzania, April, 2012, Accra, Ghana, July, 2012, Mombassa, Kenya October 2017, Dakar, Senegal April 2019

Panel member. Witt, D. Lundstrom, T. The Infected Healthcare Worker: Practice vs. Recommendations. Association for Professionals in Infection Control and Epidemiology, Annual Meeting, June 7, 2014. Anaheim, CA. Invited speaker

Panel member. Private Health System Perspectives on the National Capability to Respond to Threats to Health, Safety, and Security. Engaging the Private Sector Health Care System in Building Capacity to Respond to Threats to the Public's Health and National Security: A Workshop March 20-21, 2018. National Academy of Medicine. Washington, DC

PUBLICATIONS, PEER REVIEWED

Witt D., Olans RN, Bacteremic W-135 meningococcal pneumonia. American Review of Respiratory Disease, 1982; 125:255-257.

Witt D., Accuracy about AIDS. The Nation 1985; 241:330. (Letter).

Vogt MV, Witt DJ, Craven DE, Byington R, Crawford DF, Schooley RT, Hirsch MS, Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS, The Lancet, 1986; 1:525-527.

Witt DJ, Craven DE, McCabe WR, Bacterial infection in adults with acquired immunodeficiency syndrome or AIDS-related complex, Clinical Research 1985; 33: 765A and Clin Res 1986; 34: 539A.

Witt DJ, Craven DE, McCabe WR, Bacterial infections in adult patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). American Journal of Medicine, 1987; 82:900-906

Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Hutchinson MS, Schooley RT, Hirsch MS, Isolation pattern of human immunodeficiency virus (HIV) from cervical secretions during the menstrual cycle of women at risk for AIDS, Annals of Internal Medicine, 1987; 106:380-387.

Archibald DW, Witt DJ, Craven DE, Vogt MW, Hirsch MS, Essex M, Antibodies to HTLVIII/LAV in cervical secretions of women at risk for AIDS, Journal of Infectious Diseases, 1987; 156:240-241.

Witt DJ, Transcription Services in the ED: American Journal of Emergency Medicine, January 1995; 13: 34-36.

Witt DJ, Role of Observation Units in The Emergency Department, Cost Effective Emergency Medicine, 1995; 1:3.

Witt DJ, More on Babesiosis and Immunodeficiency. Annals of Emergency Medicine, 1995; 26:239-240. (Letter)

Witt DJ, Post-Tsunami Malaria in Indonesia-The Pivotal Contributions of Permanente Physicians. The Permanente Journal. 2005;9(4):87-9.

Witt DJ, On the Use of Rapid Diagnostic Test Kits for Malaria (Commentary). The Permanente Journal. 2007;11(2):68.

Witt, MA, Katz, PH, Witt, DJ. Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Preadolescents in a North American Outbreak. Clinical Infectious Diseases 2012;54(12): 1730-1735

Witt, MA, Katz, PH, Witt, DJ. Reply to Misegades et al, Guiso, and Sheridan et al. Clinical Infectious Diseases 2012;55(10):1435-1436.

Witt, DJ, Nonpayment for Preventable Infections in U.S. Hospitals. N Engl J Med 2013; 368:191. (Letter)

Witt, MA, Arias, L, Katz, PH, Truong, ET, Witt, DJ. Reduced Risk of Pertussis Among Persons Ever Vaccinated with Whole-cell Pertussis Vaccine Compared to Recipients of Acellular Vaccines in a Large American Cohort. Clinical Infectious Diseases, 2013;56(9);1248-1254.

Witt, DJ Barnes, S, C. difficile – A Multifaceted Approach to Prevention. Prevention Strategist. March/April 2013

Witt, MA, Katz, PH, Truong, ET, Witt, DJ Reply to Kiraly et al Clinical Infectious Diseases 2013;57(5):770-771.

Witt, MA, Katz, PH, Truong, ET, Witt, DJ Response to André, et al Clinical Infectious Diseases. first published online August 15, 2013

PUBLICATIONS, PEER REVIEWED, continued

Lai, JB., Witt, DJ, Witt, MA. P0849: Real-world effectiveness of sofosbuvir (SOF), telaprevir, and boceprevir (T, B) based therapy for hepatitis C virus (HCV): An analysis in a large integrated health care system. *Journal of Hepatology*. 2015;62:S658-S658.

Lai, J.B., Witt, M.A., Pauly, MP, Ready J, Allerton M, Seo S, Witt DJ. Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System. *Drugs* 2017;77: 313. doi:10.1007/s40265-016-0684-y

Olans, RD, Olans, RN, Witt, DJ, Good Nursing Is Good Antibiotic Stewardship. *Am J Nursing*. 2017; 117(8):58-63.

Marcus JL, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, Lai JB, Lam JO, Pauly MP, Quesenberry CP Jr., Ready J, Saxena V, Seo S, Witt DJ, Silverberg MJ. No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. *Clin Gastroenterol Hepatol*. 2018 Mar 11. pii: S1542-3565(18)30255-6. doi: 10.1016/j.cgh.2018.03.003

Marcus, JL, Hurley, LB, Chamberland, S, Champsi, JH, Gittleman, LC, Korn, DG, Lai, JB, Lam, JO, Pauly, MP, Quesenberry, CP, Ready, J, Saxena, V, Seo, SI, Witt, DJ, Silverberg, MJ. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. *Public Health Reports*. 2018;133(4):452-460. doi:10.1177/0033354918772059.

Scaletta, JM, James Davis, J, Charu Malik, M, Witt, DJ. Reasons for rejection of abstracts submitted to the Annual Conference of the Association for Professionals in Infection Control and Epidemiology: Ensuring transparency and encouraging quality. *Am J Infect Control* 2019;47:471-3. doi:10.1016/j.ajic.2018.09.022

Lam JO, Hurley LB, Chamberland S, Champsi J, Gittleman LC, Korn D, Lai JB, Quesenberry CP, Ready J, Saxena V, Seo S, Witt D, Silverberg MJ, Marcus JL. (2019). Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. *International Journal of STD & AIDS*. <https://doi.org/10.1177/0956462419836520>

Seo S, Silverberg MJ, Hurley LB, Ready J, Saxena V, Witt D, Hare CB, Champsi JH, Korn DG, Pauly MP, Chamberland S, Lai JB, Marcus JL. Prevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017. *Clin Gastroenterol Hepatol*. 2019;S1542-3565(19)30425-2. doi:10.1016/j.cgh.2019.04.035

Lacerna, C, Patey, D, Block, L, Naik, S, Kevorkova, Y, Galin, J, Parker, M, Betts, R, Parodi, S, Witt, D. A Successful Program Preventing Non-Ventilator Hospital Acquired Pneumonia in A Large Hospital System. *Infect Control Hosp Epidemiol*. 2020;41(5):547552. doi.org/10.1017/ice.2019.368

Marcus, JL, Hurley, LB, Chamberland, S, Champsi, JH, Korn, DG, Lai, JB, Lam, JO, Quesenberry, Jr, CP, Ready, J, Saxena, V, Seo, SI, Witt, DJ, Silverberg, MJ. Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007–2017. *Open Forum Infectious Diseases*, 2020;7(2):044. <https://doi.org/10.1093/ofid/ofaa044>

Marcus JL, Hurley LB, Chamberland S, Champsi, JH, Gittleman, LC, Korn, DG, Lai, JB, Lam, JO, Pauly, MP, Quesenberry, Jr, CP, Ready, J, Saxena, V, Seo, SL, Witt, DJ, Silverberg, MJ. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. *Public Health Reports*. 2018;133(4):452-460. doi:10.1177/0033354918772059

#### ABSTRACTS AND ORAL PRESENTATIONS

Witt DJ, Flannery BL, Craven DE, McCabe WR. Bacterial infections in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). *Clinical Research*, 1985; 33(3):765A. (Abstract).

Vogt MW, Witt DJ, Craven DE, Byington R, Schooley RT, Hirsch MS, Isolation of LAV/HTLV-III from female genital secretions, International Conference on Acquired Immunodeficiency Syndrome (AIDS), Paris, France, June 25, 1986. (Abstract).

Witt DJ, Vogt MW, Hutchison MS, Hirsch MS, Craven DE, Clinical and virologic evaluation of pregnant women with antibody to human T-lymphotropic virus, type III, Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., September 29, 1986. (Abstract)

Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Hirsch MS, Pattern of HTLV-III isolation from cervical secretions during the menstrual cycle of women at risk for AIDS, Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., September 30, 1986. (Abstract)

Witt DJ, A prospective evaluation of transcription services in an Emergency Department, American College of Physician Executives, San Francisco, CA., May 9, 1992 (abstract)

Witt DJ, Rieg L, St John R, Carrejo A, Hyatt R, Multi-Faceted Patient and Provider Education Dramatically Reduced Inappropriate Antibiotic Prescribing with Improvement in *S. pneumoniae* Susceptibility: Results of a 3-Year Intervention Program in a Large HMO, 43<sup>rd</sup> Annual Meeting, Infectious Diseases Society of America, Boston, MA, October 8, 2004. (Abstract)

Truong, E, Lai, J, Witt, D. Clinical Management of HIV-Positive Patients By a HIV Specialist Physician With or Without Clinical Pharmacist Support. California Society of Hospital Pharmacists. Anaheim, CA, October 10, 2008. (Abstract)

Witt, MA, Katz, PH, Witt, D. Frequent Acellular Pertussis Vaccine Failure in 8-14 Yearolds in a North American Outbreak. 51<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 20, 2011. (Oral presentation, abstract)

ABSTRACTS AND ORAL PRESENTATIONS, continued

Witt, MA, Katz, PH, Witt, D. Inferior Protection from Clinical Pertussis Among Persons Receiving Solely Acellular Pertussis (aP) Vaccine Contrasted with those Receiving One or More Doses of Whole-cell Pertussis Vaccine (wP) as Part of Their Primary Vaccine Series. 51<sup>st</sup> Annual Meeting, Infectious Diseases Society of America, San Diego, CA October 20, 2012. (Oral presentation, abstract)

Gonella, N, Worth, A, Witt, M, Witt, D, Prasad, S. Statin Continuation Reduces ICU Length of Stay and May Improve Survival in Bacteremia- A Pilot Study. 43rd Critical Care Congress, San Francisco, CA January 9, 2013 (abstract)

Lai, JB., Witt, DJ, Real-World Effectiveness of Ledipasvir (LDV)/Sofosbuvir (SOF)-Based Therapy for Hepatitis C Virus (HCV): Preliminary Analysis in a Large Integrated Health Care System. American Association for the Study of Liver Disease, The Liver Meeting. November 15, 2015, San Francisco, CA. <http://www.aasld.org/events-professionaldevelopment/liver-meeting/scientific-program/poster2#HEPC> (abstract)

Prasad, S, Wang, E, Witt, DJ, Gentamicin Induces the Formation and Alters the Composition of Gram-Negative Rod Biofilms. This Process is Blocked by Erythromycin Co-Treatment. American Thoracic Society International Meeting, May 16, 2016. San Francisco, CA. (oral presentation)

Lai, JB, Witt, MA, Witt, DJ. Real-World Effectiveness of 8, 12 and 24 Weeks Ledipasvir (LDV)/Sofosbuvir (SOF)-Based Therapy for Hepatitis C Virus (HCV) Genotype 1: Analysis in a Large Integrated Health Care System. International Liver Congress, April 15, 2016. Barcelona, Spain. (abstract)

Matthys, A, Gilani, M, Witt, D, Prasad, S. Inhaler Utilization in Advanced COPD. Chest 2016;150(4):923a. <http://dx.doi.org/10.1016/j.chest.2016.08.1023> (Oral Presentation)

Marcus, JL, Hurley, LB, Chamberland, S, Champsi, JH, Gittleman, LC, Korn, DG, Lai, J, Quesenberry, Jr., CP, Ready, J, Saxena, V, Seo, S, Witt, DJ, Silverberg, MJ. Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population. ID Week, October 5, 2017. San Diego, CA (abstract)

Lai, JB, Witt, MA, Ready, J, Pauly, MA, Witt, DJ. Obesity and High Body Weights Predict Ledipasvir/Sofosbuvir Treatment Failure. The Liver Meeting, October 21, 2017. San Francisco, CA (Abstract)

Lam, JO, Hurley, LB, Chamberland, S, Champsi, JH, Gittleman, LC, Korn, DG, Lai, JB, Pauly, MP, Quesenberry, CP, Ready, J, Saxena, V, Seo, SI, Witt, DJ, Silverberg, MJ, Marcus, JL. Hepatitis C Treatment Uptake Among Insured HIV/HCV-Coinfected Patients. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 7, 2018. Boston, MA. (Abstract)

ABSTRACTS AND ORAL PRESENTATIONS, continued

Saxena, V, Chamberland, S, Hurley, L, Lai, JB, Truong, E, Marcus, J, Champsi, J, Hare, B, Korn, D, Ready, J, Seo, S, Witt, D, Silverberg, M. Real-World Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir in Hepatitis C Infected Patients. The Liver Meeting, November 10, 2018. San Francisco, CA (Abstract)

Marcus, J, Hurley, L, Chamberland, S, Champsi, J, Gittleman, L, Korn, D, Lai, J, Quesenberry, C, Ready, J, Saxena, V, Seo, S, Witt, D, Silverberg, M. Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population, Open Forum Infectious Diseases, Volume 4, Issue suppl\_1, 1 October 2017, Pages S198, <https://doi.org/10.1093/ofid/ofx163.380> (Abstract)

Naik, S, Lacerna, C, Kevorkova, Y, Galin, J, Patey, D, Block, L, Parker, M, Betts, R, Parodi, S, Witt, D. Significant Reduction of Non-Ventilator Hospital Acquired Pneumonia (HAP) with a Prevention Bundle and Clinical and Leadership Feedback in a Large Integrated Healthcare System. ID Week 2019. Washington, DC October 4, 2019. (Abstract)